Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2020

View Archived Issues

Distinguishing real from backseat drivers

Blocking bad bone

Discovery of macrocyclic ASK1 inhibitors with potential applications in neurodegenerative diseases

SLC25A1 plays a role in the pathogenesis of fatty liver disease and is a druggable target

Arbutus discontinues development of its first generation oral HBV RNA-destabilizer

Myovant reports positive one-year data from phase III LIBERTY extension study

Rezolute initiates phase IIb study of RZ-358 in congenital hyperinsulinism

Promising preclinical data presented for AdC-gDE765dt vaccine

Taiho Pharmaceutical presents phase I data for TAS-0313 cancer peptide vaccine

Initial phase I data for binimetinib plus pembrolizumab in TNBC

First data presented for UV-1 cancer vaccine combined with ipilimumab in malignant melanoma

Newly identified HIV broadly neutralizing antibody is hard to escape

Intellia presents new results for its cell therapy development programs

Phenex Pharmaceuticals AG patents new AhR antagonists

BeiGene discloses adenosine A2A receptor antagonists

Sestrins protect against muscle wasting by coordinating anabolic and catabolic pathways

Merck KGaA presents PSMB8 inhibitors

Roche describes new oligonucleotides targeting Spi1 proto-oncogene

Intrexon patents ROR1-targeting CARs

Primary objective met in phase II study of TTP-399 in type 1 diabetes

Phase III trial of troriluzole in generalized anxiety disorder misses primary endpoint

FDA accepts IND for phase I/II study of Inovio's INO-3107 for recurrent respiratory papillomatosis

Health Canada clears Bold to begin phase Ib study of BOLD-100 in gastrointestinal cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...